Quick Takeaways
- GSK plc filed SCHEDULE 13D for CureVac N.V. Common Shares, par value (euro) 0.12 per share (CVAC).
- Disclosed ownership: 74%.
- Date of event: 07 Aug 2025.
GSK plc - 07 Aug 2025 SCHEDULE 13D Report for CureVac N.V. Common Shares, par value (euro) 0.12 per share (CVAC)
- Filing Manager
- GSK plc
- Reporting Manager
- GSK plc
- Symbol
- CVAC
- Shares outstanding
- 22,421,536 shares
- Disclosed Ownership
- 16,591,937 shares
- Ownership
- 74%
- Form type
- SCHEDULE 13D
- Filing time
- 13 Aug 2025, 18:05:21 UTC
- Date of event
- 07 Aug 2025
- Next filing
- 05 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GSK plc disclosed 74% ownership in CureVac N.V. Common Shares, par value (euro) 0.12 per share (CVAC) on 07 Aug 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Aug 2025, 18:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GSK plc | 74% | 16,591,937 | 16,591,937 | 0 | /s/ Victoria A. Whyte | Victoria A. Whyte, Authorized Signatory | 0001131399 |